# A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer

> **NCT07714668** · PHASE2 · RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 171 (estimated)

## Conditions studied

- Ovarian Cancer
- Recurrent Ovarian Cancer

## Interventions

- **DRUG:** SYS6041, bevacizumab
- **DRUG:** SYS6041, carboplatin, bevacizumab
- **DRUG:** paclitaxel, carboplatin, bevacizumab
- **DRUG:** SYS6041, enlonstobart, bevacizumab

## Key facts

- **NCT ID:** NCT07714668
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-13
- **Primary completion:** 2028-04-30
- **Final completion:** 2029-08-31
- **Target enrollment:** 171 (ESTIMATED)
- **Last updated:** 2026-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07714668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07714668, "A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07714668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*